stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Return on invested capital
Haemonetics Corporation's return on invested capital over the twelve months to 30 September 2026 was 6.31%, up 0.8 percentage points from fiscal 2026 (5.53%). Over the past ten years it has ranged from −2.83% (fiscal 2016) to 9.66% (fiscal 2025); the current reading is higher than 50% of that period. That is above the Medical Devices industry median of −5.27% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 5.53% | (4.13) |
| FY2025 | 9.66% | 3.13 |
| FY2024 | 6.53% | (1.04) |
| FY2023 | 7.57% | 2.76 |
| FY2022 | 4.81% | 0.25 |
| FY2021 | 4.56% | (3.99) |
| FY2020 | 8.55% | 2.19 |
| FY2019 | 6.36% | 0.80 |
| FY2018 | 5.56% | 6.98 |
| FY2017 | −1.42% | 1.41 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LIVN LivaNova PLC compare | 9.14% |
| HAE Haemonetics Corporation | 6.31% |
| ITGR Integer Holdings Corporation compare | 3.16% |
| BIO.B Bio-Rad Laboratories, Inc. compare | −0.44% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| AXGN AxoGen, Inc. compare | −5.27% |
| IRTC iRhythm Holdings, Inc. compare | −11.4% |
| TXG 10x Genomics compare | −20.2% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement